Type6

Type6 is a startup. Brouky classifies it under Healthcare & Life Sciences.

Type6 is developing a new class of bifunctional kinase inhibitors aimed at targeting a range of historically hard-to-target cancers using a rational engineering approach to create highly specific, high avidity molecules.